Compugen Earnings Call Highlights Trials, Cash Runway

Compugen ((CGEN)) has held its Q1 earnings call. Read on for the main highlights of the call.

Compugen’s latest earnings call struck a cautiously optimistic tone, with management highlighting clear clinical and partnership momentum despite modest near-term financials. Investors heard a story of a small biotech leveraging big‑pharma alliances, a robust cash runway and differentiated science, while acknowledging execution risk around key trials and dependence on milestone-driven income.

MAIA-ovarian Trial Marks Key Clinical Inflection

Compugen has launched its randomized MAIA-ovarian adaptive platform trial for COM701 in relapsed platinum-sensitive ovarian cancer, with all sites now open and enrolling across the U.S., Israel and France. An interim analysis of median progression-free survival is targeted by Q1 2027, and management views the study as a potential registration pathway and future combination backbone.

COM701 Shows Durable Activity and Differentiated Biology

Pooled data presented at ESMO demonstrated that COM701, both as monotherapy and in combinations, was well tolerated and produced durable responses in heavily pretreated platinum-resistant ovarian cancer patients. Management underscored COM701’s unique PVRIG biology, which appears active in both PD-L1 positive and negative tumors, potentially opening broader development opportunities.

AstraZeneca’s Rilvegostomig Progress Bolsters Upside

Partner AstraZeneca showcased multiple Rilvegostomig abstracts at AACR, including preclinical results and Phase II DESTINY-Gastric03 data suggesting promising combinability and antitumor activity. AstraZeneca has flagged non-risk-adjusted peak annual revenue potential above $5 billion, positioning Compugen for up to $195 million in future milestones plus mid-single-digit tiered royalties if the program succeeds.

Gilead’s GS-0321 Advancement Adds Another Value Stream

GS-0321, formerly COM503, is advancing through a Phase I dose-escalation trial with Gilead, and management said the study is progressing as planned. Compugen has already booked $90 million from this partnership and could receive up to $758 million more in milestones, along with potential double-digit royalties on future sales.

Unigen AI Platform Drives Pipeline and Partnerships

The Unigen computational discovery engine remains central to Compugen’s strategy, having identified targets underlying COM701, COM902 and GS-0321. Management stressed that Unigen continues to power early-stage immuno-oncology discovery, supporting new programs that could underpin future deals and keep the pipeline stocked with differentiated assets.

Cash Runway into 2029 Supports Development Push

As of March 31, 2026, Compugen held about $134.9 million in cash, equivalents, short-term deposits and marketable securities, bolstered by a $65 million nondilutive payment from AstraZeneca in late 2025. The company expects this balance to fund operations into 2029, even without additional inflows, giving it room to advance MAIA-ovarian and partnered programs.

Revenue Slips Slightly on Small Base

First-quarter 2026 revenue came in at roughly $2.2 million, down about 4.35% from $2.3 million a year earlier, reflecting timing of upfront and IND-related milestone recognition from the Gilead deal. Management acknowledged that the company remains a development-stage enterprise with a modest revenue base, leaving upside tied to future milestones and royalties.

R&D Spending Climbs with Clinical Expansion

Research and development expenses rose to approximately $6.9 million in Q1 2026 from $5.8 million in Q1 2025, an increase of about 19%. The company attributed the higher spend mainly to clinical costs associated with the MAIA-ovarian study and increased drug supply needs, signaling a deliberate ramp in investment behind its lead programs.

Net Loss Widens as Investment Cycle Deepens

Compugen reported a net loss of about $7.7 million, or $0.08 per share, in Q1 2026 versus roughly $7.2 million, or $0.08 per share, in the prior-year quarter. The roughly 6.9% deterioration highlights the cost of stepping up R&D, though management framed the losses as manageable given the multiyear cash runway and partnership economics.

Reliance on Milestones Highlights Execution Risk

With quarterly revenue around $2.2 million, Compugen’s financial trajectory is heavily linked to the timing and success of milestone payments and future royalties from AstraZeneca and Gilead. Investors are effectively betting that these partners advance their programs toward late-stage trials and commercialization, underscoring the importance of external execution.

MAIA-ovarian Outcome and Benchmarks Remain Unclear

The MAIA-ovarian trial is event-driven and described as exploratory, with a control-arm progression-free survival benchmark of about 5.5 months based on prior studies. Management is aiming for a three-month or greater PFS improvement, but stressed that outcomes and potential adaptive design tweaks will not be clear until the interim readout expected in Q1 2027.

Limited Transparency on Enrollment Pace

While Compugen reiterated that MAIA-ovarian enrollment is on track, it declined to share specific patient counts or accrual rates. This limited transparency means that investors will have to wait for future updates to gauge whether recruitment is progressing smoothly enough to keep the interim analysis timeline intact.

Guidance Reaffirms Runway and Clinical Milestones

Management reaffirmed guidance that its roughly $134.9 million in cash and investments should fund operations into 2029, even as Q1 revenues held near $2.2 million and R&D spend climbed to about $6.9 million. On the development side, the company reiterated the MAIA-ovarian interim PFS analysis by Q1 2027, ongoing GS-0321 dose escalation and AstraZeneca’s broad Phase III program for Rilvegostomig, with sizable milestone and royalty potential from both partners.

Compugen’s call painted the picture of a small-cap biotech leaning heavily on differentiated immuno-oncology science and deep-pocketed partners to drive long-term value. With a solid balance sheet, active trials and substantial milestone optionality, the story appeals to risk-tolerant investors, though near-term results remain dependent on clinical execution and partner progress.